liu.seSearch for publications in DiVA
Change search
Link to record
Permanent link

Direct link
BETA
Ekermo, Bengt
Publications (10 of 14) Show all publications
Lieberman, L., Devine, D. V., Reesink, H. W., Panzer, S., Wong, J., Raison, T., . . . Triulzi, D. (2014). Prevention of transfusion-transmitted cytomegalovirus (CMV) infection: Standards of care. Vox Sanguinis, 107(3), 276-311.
Open this publication in new window or tab >>Prevention of transfusion-transmitted cytomegalovirus (CMV) infection: Standards of care
Show others...
2014 (English)In: Vox Sanguinis, ISSN 0042-9007, E-ISSN 1423-0410, Vol. 107, no 3, 276-311 p.Article in journal (Refereed) Published
Abstract [en]

n/a

Place, publisher, year, edition, pages
Wiley-Blackwell, 2014
National Category
Infectious Medicine Clinical Laboratory Medicine
Identifiers
urn:nbn:se:liu:diva-111751 (URN)10.1111/vox.12103 (DOI)000342623600011 ()24801438 (PubMedID)
Available from: 2014-10-31 Created: 2014-10-31 Last updated: 2017-12-05
Waldenstrom, J., Konar, J., Ekermo, B., Norder, H. & Lagging, M. (2013). Neonatal transfusion-transmitted hepatitis C virus infection following a pre-seroconversion window-phase donation in Sweden. Scandinavian Journal of Infectious Diseases, 45(10), 796-799.
Open this publication in new window or tab >>Neonatal transfusion-transmitted hepatitis C virus infection following a pre-seroconversion window-phase donation in Sweden
Show others...
2013 (English)In: Scandinavian Journal of Infectious Diseases, ISSN 0036-5548, E-ISSN 1651-1980, Vol. 45, no 10, 796-799 p.Article in journal (Refereed) Published
Abstract [en]

A 9-day-old child developed a transfusion-transmitted hepatitis C virus (HCV) infection following a pre-seroconversion window-phase donation. Retrospective analysis of donor plasma revealed detectable HCV core antigen (154 fmol/l), as well as HCV RNA (87,000 IU/ml). Of 5.24 million Swedish plasma samples from December 1998 to September 2012, 5 additional window-phase donations were identified.

Place, publisher, year, edition, pages
Informa Healthcare, 2013
Keyword
Hepatitis C virus, transfusion transmission, core antigen, NAT, cost effectiveness
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-99396 (URN)10.3109/00365548.2013.797601 (DOI)000324579200011 ()
Note

Funding Agencies|Swedish Medical Research Council|2011-3821|ALF Funds|ALFGBG-3149|

Available from: 2013-10-17 Created: 2013-10-17 Last updated: 2017-12-06
Roth, W. K., Busch, M. P., Schuller, A., Ismay, S., Cheng, A., Seed, C. R., . . . Reesink, H. W. (2012). International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009.. Vox Sanguinis, 102(1), 82-90.
Open this publication in new window or tab >>International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009.
Show others...
2012 (English)In: Vox Sanguinis, ISSN 0042-9007, E-ISSN 1423-0410, Vol. 102, no 1, 82-90 p.Article in journal (Refereed) Published
Place, publisher, year, edition, pages
Wiley-Blackwell, 2012
National Category
Hematology
Identifiers
urn:nbn:se:liu:diva-88580 (URN)10.1111/j.1423-0410.2011.01506.x (DOI)000298602400012 ()21933190 (PubMedID)
Note

Bengt Ekermo LiU författare nr 63

Available from: 2013-02-12 Created: 2013-02-12 Last updated: 2017-12-06
Malm, K., Ekermo, B., Hillgren, K., Britton, S., Fredlund, H. & Andersson, S. (2012). Prevalence of human T-lymphotropic virus type 1 and 2 infection in Sweden. Scandinavian Journal of Infectious Diseases, 44(11), 852-859.
Open this publication in new window or tab >>Prevalence of human T-lymphotropic virus type 1 and 2 infection in Sweden
Show others...
2012 (English)In: Scandinavian Journal of Infectious Diseases, ISSN 0036-5548, E-ISSN 1651-1980, Vol. 44, no 11, 852-859 p.Article in journal (Refereed) Published
Abstract [en]

Background: Prevalence data on human T-lymphotropic virus types 1 and 2 (HTLV-1/2) in Sweden have not been updated since 1995. The seroprevalence among blood donors at that time was 0.2/10,000. A few years earlier, a high prevalence of HTLV-2 was found in intravenous drug users (IDUs) in Stockholm (3.4%). The objective of this study was to update information on the seroprevalence of HTLV in several study groups. Methods: Serum samples from pregnant women, hepatitis C virus (HCV)-positive individuals, and IDUs in Stockholm were investigated for HTLV-1/2 antibodies. Data from the mandatory HTLV-1/2 screening (2003-2006) of in vitro fertilization (IVF) clients were compiled, as well as data from new blood donors. Results: Eight out of 35,000 IVF patients were positive for anti-HTLV-1/2 (seroprevalence 2.3 per 10,000). Of the anti-HCV-positive individuals (n = 355), 1 sample was HTLV-1-positive (28.2 per 10,000). From 1995 to 2007, 18 HTLV-positive new blood donors were identified out of approximately 550,000 individuals tested (0.3 per 10,000). Thirty-five of 1079 tested IDUs were screening reactive. Conclusions: Since the start of screening in 1994, there has been no increased seroprevalence of HTLV-1/2 among blood donors in Sweden. Seroprevalence among Swedish IVF patients is 10 times higher than among blood donors. This finding is comparable to a 2003 European seroprevalence study of pregnant women in 7 countries. However, the possibility that the IVF group includes individuals with a higher risk of acquiring sexually transmitted infections, including HTLV, than the general population cannot be ruled out.

Place, publisher, year, edition, pages
Informa Healthcare, 2012
Keyword
HTLV-1/2, prevalence, IDU, blood donors, IVF
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-85625 (URN)10.3109/00365548.2012.689847 (DOI)000310008900008 ()
Available from: 2012-11-26 Created: 2012-11-26 Last updated: 2017-12-07
Benjamin, R. J., Bianco, C., Seed, C. R., Yang, H., Lee, J., Keller, A. J., . . . Reesink, H. W. (2011). Deferral of males who had sex with other males. Vox Sanguinis, 101(4), 339-367.
Open this publication in new window or tab >>Deferral of males who had sex with other males
Show others...
2011 (English)In: Vox Sanguinis, ISSN 0042-9007, E-ISSN 1423-0410, Vol. 101, no 4, 339-367 p.Article in journal (Refereed) Published
Abstract [en]

n/a

Place, publisher, year, edition, pages
Wiley-Blackwell, 2011
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-71634 (URN)10.1111/j.1423-0410.2011.01489.x (DOI)000295833100005 ()
Available from: 2011-10-27 Created: 2011-10-27 Last updated: 2017-12-08
Davidson, T., Ekermo, B., Gaines, H., Lesko, B. & Akerlind, B. (2011). The cost-effectiveness of introducing nucleic acid testing to test for hepatitis B, hepatitis C, and human immunodeficiency virus among blood donors in Sweden. TRANSFUSION, 51(2), 421-429.
Open this publication in new window or tab >>The cost-effectiveness of introducing nucleic acid testing to test for hepatitis B, hepatitis C, and human immunodeficiency virus among blood donors in Sweden
Show others...
2011 (English)In: TRANSFUSION, ISSN 0041-1132, Vol. 51, no 2, 421-429 p.Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: The purpose of this study was to estimate the cost-effectiveness of using individual-donor nucleic acid testing (ID-NAT) in addition to serologic tests compared with the sole use of serologic tests for the identification of hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) among blood donors in Sweden. STUDY DESIGN AND METHODS: The two strategies analyzed were serologic tests and ID-NAT plus serologic tests. A health-economic model was used to estimate the lifetime costs and effects. The effects were measured as infections avoided and quality-adjusted life-years (QALYs) gained. A societal perspective was used. RESULTS: The largest number of viral transmissions occurred with serologic testing only. However, the risks for viral transmissions were very low with both strategies. The total cost was mainly influenced by the cost of the test carried out. The cost of using ID-NAT plus serologic tests compared to serologic tests alone was estimated at Swedish Krona (SEK) 101 million (USD 12.7 million) per avoided viral transmission. The cost per QALY gained was SEK 22 million (USD 2.7 million). CONCLUSION: Using ID-NAT for testing against HBV, HCV, and HIV among blood donors leads to cost-effectiveness ratios that are far beyond what is usually considered cost-effective. The main reason for this is that with current methods, the risks for virus transmission are very low in Sweden.

Place, publisher, year, edition, pages
Blackwell Publishing Ltd, 2011
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-66115 (URN)10.1111/j.1537-2995.2010.02877.x (DOI)000287199400026 ()
Available from: 2011-03-04 Created: 2011-03-04 Last updated: 2012-03-27Bibliographically approved
Almroth, G., Ekermo, B., Åkerlind, B., Månsson, A.-S. & Widell, A. (2010). Monitoring hepatitis C infection in a major Swedish nephrology unit and molecular resolution of a new case of nosocomial transmission.. Journal of medical virology, 82(2), 249-256.
Open this publication in new window or tab >>Monitoring hepatitis C infection in a major Swedish nephrology unit and molecular resolution of a new case of nosocomial transmission.
Show others...
2010 (English)In: Journal of medical virology, ISSN 1096-9071, Vol. 82, no 2, 249-256 p.Article in journal (Refereed) Published
Abstract [en]

Hepatitis C virus (HCV) infection is a frequent problem in hemodialysis units. The prevalence and incidence of HCV infection over a decade were studied in a nephrology unit affected by previous nosocomial HCV transmission. The HCV non-structural 5B protein gene was sequenced to achieve phylogenetic analysis of a new (incident) case of infection. Proportions of patients who were and were not infected with HCV remained similar over the period, as did the inflow and outflow of patients infected previously. In 1997, 12/157 (8%) of patients at the unit (treatment: hemodialysis, peritoneal dialysis, and renal transplant recipients) were positive in HCV RNA, whereas in 2007 the overall number was 9/239 (4%). One patient acquired an HCV infection, and the NS5B sequence in that case clustered with genotype 2b sequences found in patients from an earlier outbreak. Comparing the HCV from the incident patient with several stored longitudinal samples and cloned PCR products from the most likely source patient revealed close phylogenetic relationship with an HCV quasispecies member from the possible source. The source patient and the incident newly infected patient were not scheduled on the same dialysis shift, although the records showed that simultaneous treatment occurred on two occasions during the months preceding transmission. In conclusion, over the 10-year period, the proportion of HCV-infected patients at the unit was unchanged. Only one new infection occurred, which originated from a fellow patient's quasispecies. This establishes phylogenetic analysis as a valuable tool for tracing patient sources of HCV transmission.

National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-53071 (URN)10.1002/jmv.21683 (DOI)20029812 (PubMedID)
Available from: 2010-01-15 Created: 2010-01-15 Last updated: 2011-02-04
Reesink, H. W., Panzer, S., Wendel, S., Levi, J. E., Ullum, H., Ekblom-Kullberg, S., . . . Kleinman, S. (2010). The use of malaria antibody tests in the prevention of transfusion-transmitted malaria. VOX SANGUINIS, 98(3), 468-478.
Open this publication in new window or tab >>The use of malaria antibody tests in the prevention of transfusion-transmitted malaria
Show others...
2010 (English)In: VOX SANGUINIS, ISSN 0042-9007, Vol. 98, no 3, 468-478 p.Article in journal (Refereed) Published
Abstract [en]

n/a

National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-54599 (URN)10.1111/j.1423-0410.2009.01301.x (DOI)000275530800011 ()
Available from: 2010-03-26 Created: 2010-03-26 Last updated: 2011-02-04
Tynell, E., Norda, R., Ekermo, B., Sanner, M., Andersson, S. & Bjorkman, A. (2007). False-reactive microbiologic screening test results in Swedish blood donors - how big is the problem? A survey among blood centers and deferred donors. Transfusion, 47(1), 80-89.
Open this publication in new window or tab >>False-reactive microbiologic screening test results in Swedish blood donors - how big is the problem? A survey among blood centers and deferred donors
Show others...
2007 (English)In: Transfusion, ISSN 0041-1132, E-ISSN 1537-2995, Vol. 47, no 1, 80-89 p.Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Screening of blood donors for markers of transfusion-transmissible infectious agents leads to a varying number of false-reactive test results and sometimes thereby temporary or permanent deferral of donors and also to loss of collected units. STUDY DESIGN AND METHODS: Data on false-reactive screening test results in 2002 and 2003 were collected from 19 blood centers in Sweden. A questionnaire was sent to donors deferred because of false-reactive screening test results to investigate their perception of the information and their reaction to the deferral. RESULTS: Testing of 21,189 samples from new donors and 423,543 donations from regular and/or repeat donors produced 1,059 false-reactive test results, mostly from hepatitis C virus antibody testing, and 299 deferrals. Six different human immunodeficiency virus tests led to between 0.02 and 0.2 percent false-reactive results. The deferral rate varied considerably between different counties. Of 204 deferred donors contacted, 180 (88%) answered the questionnaire. More than 80 percent were worried about their test results and worry was more common among those who did not feel sufficiently informed. CONCLUSION: The results imply that there is a need for a more standardized approach to the screening of blood donors and donations with the aim of minimizing the number of false-reactive screening test results. They also emphasize the importance of appropriate information and support to deferred donors.

National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-45978 (URN)10.1111/j.1537-2995.2007.01067.x (DOI)
Available from: 2009-10-11 Created: 2009-10-11 Last updated: 2017-12-13
Lithander, E. & Ekermo, B. (2003). Kontroll av blod och blodgivare. (1ed.). In: Karl Ekdahl och Johan Giesecke (Ed.), Smittskyddsboken: (pp. 134-138). Linköping: Linköpings universitet.
Open this publication in new window or tab >>Kontroll av blod och blodgivare.
2003 (Swedish)In: Smittskyddsboken / [ed] Karl Ekdahl och Johan Giesecke, Linköping: Linköpings universitet , 2003, 1, 134-138 p.Chapter in book (Other academic)
Abstract [sv]

De senaste 10 åren har medfört stora förändringar av betydelse för svenskt smittskydd. Genom ökat resande och invandring har vårt infektionspanorama blivit mer internationellt. Tidigare okända smittsamma sjukdomar (senast SARS) har identifierats samtidigt som polio officiellt förklarats utrotad i Europa. En ökande andel av bakterier och virus har blivit resistenta mot antibiotika men andelen barn som vaccineras mot framför allt mässling har börjat sjunka ned mot kritiska nivåer. Samtidigt har den avsiktliga spridningen av antrax i USA blixtbelyst samhällets sårbarhet och de möjliga konsekvenserna av bioterrorism. Medlemskapet i EU har också inneburit förändringar av hur övervakning av smittsamma sjukdomar sköts i Sverige. De ökade krav som dessa förändringar ställer på alla de personer som på ett eller annat sätt arbetar med smittskyddsfrågor har satt behovet av utbildning i fokus.Smittskyddsboken ska ge en samlad översikt över alla de aktörer och insatser som tillsammans gör att det svenska smittskyddet står sig så väl i alla internationella jämförelser. Tanken är också att boken ska vara tillräckligt detaljerad för att kunna fungera som en praktisk handbok för flertalet av de smittskyddsspörsmål som kan dyka upp. I stället för ingående sjukdomsbeskrivningar har vi i ett appendix listat alla de viktigaste smittsamma sjukdomarna, även här med fokus på smittvägar, inkubationstider och möjliga smittskyddsåtgärder.

Place, publisher, year, edition, pages
Linköping: Linköpings universitet, 2003 Edition: 1
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-26686 (URN)11253 (Local ID)91-44-04197-7 (ISBN)978-9-1440-4197-1 (ISBN)11253 (Archive number)11253 (OAI)
Available from: 2009-10-08 Created: 2009-10-08 Last updated: 2013-11-12Bibliographically approved
Organisations

Search in DiVA

Show all publications